Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Biorxiv : the Preprint Server for Biology|July 3, 2023
Biochemical, biomarker, and behavioral characterization of the <i>Grn</i><sup></sup> mouse model of frontotemporal dementiaDenise M Smith, Geetika Aggarwal, Michael L Niehoff, et al.
Lupus Science & Medicine|June 1, 2025
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trialMarta Mosca, Laurent Arnaud, Anca Askanase, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging studyMichael E Weinblatt, Philip Mease, Eduardo Mysler, et al.
RMD Open|June 28, 2019
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a <i>post hoc</i> analysis of a phase III trialIain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, et al.
Annals of the Rheumatic Diseases|May 6, 2017
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisPhilip J Mease, Alice B Gottlieb, Désirée van der Heijde, et al.
Pharmacological Reviews|March 5, 2013
Nuclear receptors and their selective pharmacologic modulatorsThomas P Burris, Laura A Solt, Yongjun Wang, et al.
Clinical Pharmacology in Drug Development|February 19, 2020
Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic DosingWeiguo Cai, Tarek A Leil, Leonid Gibiansky, et al.
Arthritis Research & Therapy|February 17, 2022
Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abataceptHarris A Ahmad, Joshua F Baker, Philip G Conaghan, et al.
The Journal of Dermatology|March 11, 2025
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trialsAkimichi Morita, Shinichi Imafuku, Yayoi Tada, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2018
Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffoldShaimaa S Goher, Kristine Griffett, Lamees Hegazy, et al.
Pageof 14